BGV1
New vaccine for a paradigm shift in Brucellosis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BGV1 project word cloud
Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.
Project "BGV1" data sheet
The following table provides information about the project.
| Coordinator |
BRUCELLA GREEN VAC SL
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-12-01 to 2019-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | BRUCELLA GREEN VAC SL | ES (MUTILVA) | coordinator | 50˙000.00 |
Map
Project objective
Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-income countries accounting in more than €3bn per year. In humans, there are 500,000 new cases annually requiring long-term hospital treatments. Brucellosis is endemic in most Asia, Africa and LATAM and is prevalent in the EU Mediterranean regions. Also, outbreaks may take place anywhere in a global world with international trading, people travelling all around the world and potential threat of bioterrorism.
Since human vaccines are not available, the most rational approach for preventing human brucellosis is the control and eradication of infection in animals. Animal vaccines are an essential tool, but existing vaccines own some inconveniences, such as residual virulence, complex management systems and costly diagnostic techniques that are not appropriate for developing countries; in Europe, control programs are based in tests for animal check-ups and compensation to farmers for slaughter of the infected animals, with vaccination prohibited or highly restricted to areas with higher prevalence of Brucellosis. These inconveniences recommended the development of new candidate vaccines.
We are developing BGV1, a patented vaccine that has the potential of allowing, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. It also simplifies existing vaccine management systems as it can be used without interfering standard diagnostic techniques. In our 5-year forecast, we estimate accumulated revenue and net profits of €58.29m and €15.13m, a conservative projection by just reaching 86.02m animals that represent only 3.92% of our TAM, generating 1.76bn economic benefits to our users.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.